Search results
Showing 1171 to 1185 of 1242 results for public health guidance
In development Reference number: GID-TA11760 Expected publication date: TBC
Transperineal biopsy for diagnosing prostate cancer (HTG680)
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
The EQ-5D is a short questionnaire used to understand how a person’s health affects their quality of life. It is used in health research and to help inform decisions about healthcare treatments.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.
Discontinued Reference number: GID-TAG387
A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving transplant.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.
View recommendations for HTG659Show all sections